Keith Flaherty, MD's lecture at STO Annual Meeting 2010 In metastatic colon cancer with BRAF V600E mutations, the spectrum of response is more heterogeneous and suggests that the repertoire of concomitant oncogene and tumor suppressor gene alterations will influence response to targeted therapy across various
Link to this comment:
All Comments (0)